Clinical Trial Update: rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating rhGAA (alglucosidase alfa) in infants with Glycogen Storage Disease Type II (Pompe disease).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ii

Drugs mentioned

• Myozyme (alglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Glycogen Storage Disease Type II, Pompe Disease | Phase 1, Phase 2 | Status: COMPLETED